Jpmorgan Chase & CO Atea Pharmaceuticals, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding AVIR
# of Institutions
111Shares Held
51.5MCall Options Held
71.8KPut Options Held
318K-
Black Rock Inc. New York, NY9.12MShares$30.6 Million0.0% of portfolio
-
Bml Capital Management, LLC Zionsville, IN6.65MShares$22.3 Million13.11% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA5.44MShares$18.2 Million0.64% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.72MShares$15.8 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA4.48MShares$15 Million1.81% of portfolio
About Atea Pharmaceuticals, Inc.
- Ticker AVIR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 83,258,600
- Market Cap $279M
- Description
- Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...